Literature DB >> 2986033

Treatment of rats with the TRH analog MK-771. Down-regulation of TRH receptors and behavioral tolerance.

S M Simasko, A Horita.   

Abstract

The regulation of receptors for thyrotropin-releasing hormone (TRH) in the central nervous system (CNS) was studied by administering the TRH analog, MK-771 to rats by three different schedules and then measuring changes in the binding of [3H](3MeHis2) TRH and behavioral responses to a challenge with MK-771. The behavioral responses monitored were wet-dog shakes, large motor movements, small motor movements and forepaw tremor. Temperature changes were also monitored. The first schedule consisted of intracerebroventricular (i.c.v.) administration of MK-771 for seven days (5 micrograms/microliter per hr) via a mini-osmotic pump. At the end of the treatment, rats showed no shaking or large motor movements typically induced by TRH, in response to a 5 mg/kg (i.p.) challenge of MK-771. Receptors were found to be 50% of control levels in the three areas of brain examined. The second schedule consisted of the administration of MK-771 (5 micrograms/2 microliters, i.c.v., once a day and 2 mg/kg, i.p., once a day). It was found that the number of receptors decreased on about the same time course as development of tolerance to wet-dog shakes and large motor movements. The third schedule consisted of the administration of MK-771 (5 micrograms/2 microliters, i.c.v.) once every 2 hr to a total of four doses. These animals eventually developed tolerance to the wet-dog shakes produced by the subsequent challenge with MK-771 and also showed a 50% decrease in receptor binding after the fourth exposure.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2986033     DOI: 10.1016/0028-3908(85)90175-3

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  4 in total

1.  Comparative efficacy and safety of intravenous and oral administration of a TRH analogue (RX77368) in motor neuron disease.

Authors:  H Modarres-Sadeghi; R J Guiloff
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-11       Impact factor: 10.154

2.  Subacute administration of a TRH analogue (RX77368) in motorneuron disease: an open study.

Authors:  H Modarres-Sadeghi; H Rogers; J Emami; R J Guiloff
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-09       Impact factor: 10.154

3.  Effect of chronic intra-accumbens administration of the TRH analogue CG3509 on histamine-induced behaviour in the rat.

Authors:  L J Bristow; G W Bennett
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

Review 4.  The Thyrotropin-Releasing Hormone-Degrading Ectoenzyme, a Therapeutic Target?

Authors:  Jean-Louis Charli; Adair Rodríguez-Rodríguez; Karina Hernández-Ortega; Antonieta Cote-Vélez; Rosa María Uribe; Lorraine Jaimes-Hoy; Patricia Joseph-Bravo
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.